Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences
08 nov. 2012 16h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Third Quarter 2012 Financial Results
07 nov. 2012 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Third Quarter 2012 Financial Results Conference Call
18 oct. 2012 16h48 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences
30 août 2012 17h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta to Present at the Canaccord Genuity 32nd Annual Growth Conference
08 août 2012 16h01 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals
03 août 2012 16h56 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Second Quarter 2012 Financial Results
02 août 2012 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Second Quarter 2012 Financial Results Conference Call
16 juil. 2012 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer
02 juil. 2012 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Decision in Teva Patent Litigation
22 juin 2012 21h02 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 22, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...